Robotic vs. Non-Robotic Single-Site Hysterectomy: Marchand Institute’s New Meta-Analysis Provides Clarity on Surgical Outcomes
FOR IMMEDIATE RELEASE
MESA, Ariz. — July 12, 2021
The Institute is very excited that our latest publication, “The Efficacy of Acetominophen for Total Laparoscopic Hysterectomy.” has been published today in the Journal of the Society of Laparoendoscopic and Robotic Surgeons (JSLS). The full text of the article is available free online at this link: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8241284/
About the Marchand Institute for Minimally Invasive Surgery
The Marchand Institute for Minimally Invasive Surgery is a 501(c)(3) tax-exempt non-profit research and educational institution based in Mesa, Arizona (EIN 42-2857240). The Institute produces peer-reviewed systematic reviews and meta-analyses in minimally invasive gynecologic surgery and women’s health, conducts FDA clinical trials, and trains surgeons through an SLS-accredited fellowship. All reviews are prospectively registered with PROSPERO, reported to PRISMA standards and appraised using the Cochrane RoB 2 tool. The Institute accepts no pharmaceutical or medical device industry funding and declares no conflicts of interest. It is directed by Greg J. Marchand, MD, FACS, FACOG, FICS.
Media Contact
Maria A. Sainz, Director of Communications and Media Relations
Marchand Institute for Minimally Invasive Surgery
maria@marchandobgyn.com | (480) 999-0905
Interview requests, expert commentary topics, boilerplate and high-resolution images: Newsroom & Press Kit. Complete publication record with DOIs and PMIDs: Publications database. Methodology: How we run a review.
###
Related posts
